Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis

The Lancet Oncology

Volumn 18, Issue 1, 2017, Pages 143-154

  Wilkerson, Julia ^a   Abdallah, Kald ^b   Hugh Jones, Charles ^c   Curt, Greg ^b   Rothenberg, Mace ^d   Simantov, Ronit ^d   Murphy, Martin ^e   Morrell, Joseph ^e   Beetsch, Joel ^f   Sargent, Daniel J ^g   Scher, Howard I ^h   Lebowitz, Peter ⁱ   Simon, Richard ^a   Stein, Wilfred D ^j   Bates, Susan E ^k,l   Fojo, Tito ^k,l  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ASTRAZENECA   (United Kingdom)

^c SANOFI   (France)

^d PFIZER INC   (United States)

^e Project Data Sphere LLC   (United States)

^f CELGENE CORPORATION   (United States)

^g MAYO CLINIC   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^j HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^k NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^l VETERANS AFFAIRS MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; AFLIBERCEPT; CABAZITAXEL; CALCITRIOL; DOCETAXEL; LENALIDOMIDE; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; SILTUXIMAB; SUNITINIB; ANTINEOPLASTIC AGENT; TAXOID; TUMOR MARKER;

ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER REGRESSION; CANCER STAGING; CASTRATION RESISTANT PROSTATE CANCER; DRUG APPROVAL; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SAMPLE SIZE; SURVIVAL TIME; TREATMENT RESPONSE; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; FOLLOW UP; KAPLAN MEIER METHOD; PATHOLOGY; PROGNOSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; CLINICAL TRIALS, PHASE III AS TOPIC; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MITOXANTRONE; NEOPLASM STAGING; PREDNISONE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAXOIDS;

EID: 85007478332     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30633-7     Document Type: Article

References (35)

1. 1 Amiri-Kordestani, L, Fojo, T, Why do phase III clinical trials in oncology fail so often?. J Natl Cancer Inst 104 (2012), 568–569.
2. 2 Blumenthal, GM, Karuri, SW, Zhang, H, et al. Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses. J Clin Oncol 33 (2015), 1008–1014.
3. 3 Michaelson, MD, Oudard, S, Ou, YC, et al. Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J Clin Oncol 32 (2014), 76–82.
4. 4 Ryan, CJ, Smith, MR, de Bono, JS, et al., for the COU-AA-302 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 368 (2013), 138–148.
5. 5 de Bono, JS, Oudard, S, Ozguroglu, M, et al., for the TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376 (2010), 1147–1154.
6. 6 Tannock, IF, de Wit, R, Berry, WR, et al., for the TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004), 1502–1512.
7. 7 Fizazi, K, De Bono, JS, Flechon, A, et al. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. Eur J Cancer 48 (2012), 85–93.
8. 8 Tannock, IF, Fizazi, K, Ivanov, S, et al., for the VENICE Investigators. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol 14 (2013), 760–768.
9. 9 Scher, HI, Jia, X, Chi, K, et al. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol 29 (2011), 2191–2198.
10. 10 Petrylak, DP, Vogelzang, NJ, Budnik, N, et al. Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 16 (2015), 417–425.
11. 11 Carvalhal, GF, Daudi, SN, Kan, D, et al. Correlation between serum prostate-specific antigen and cancer volume in prostate glands of different sizes. Urology 76 (2010), 1072–1076.
12. 12 Stein, WD, Figg, WD, Dahut, W, et al. Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data. Oncologist 13 (2008), 1046–1054.
13. 13 Stein, WD, Yang, J, Bates, SE, Fojo, T, Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage. Oncologist 13 (2008), 1055–1062.
14. 14 Stein, WD, Huang, H, Menefee, M, et al. Other paradigms: growth rate constants and tumor burden determined using computed tomography data correlate strongly with the overall survival of patients with renal cell carcinoma. Cancer J 15 (2009), 441–447.
15. 15 Stein, WD, Gulley, JL, Schlom, J, et al. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res 17 (2011), 907–917.
16. 16 Stein, WD, Wilkerson, J, Kim, ST, et al. Analyzing the pivotal trial that compared sunitinib and IFN-alpha in renal cell carcinoma, using a method that assesses tumor regression and growth. Clin Cancer Res 18 (2012), 2374–2381.
17. 17 Wilkerson, J, tumgr: Tumor Growth Rate Analysis. R package version 0.0.4. http://CRAN.R-project.org/package=tumgr, 2016 (accessed Sept 25, 2016).
18. 18 Therneau, T, A Package for Survival Analysis in S. Version 2.38. http://CRAN.R-project.org/package=survival, 2015 (accessed Sept 25, 2016).
19. 19 Anderson, JR, Cain, KC, Gelber, RD, Analysis of survival by tumor response. J Clin Oncol 1 (1983), 710–719.
20. 20 Uno, H, SurvC1: C-statistics for risk prediction models with censored survival data. R package version 1.0.2. http://CRAN.R-project.org/package=survC1, 2013 (accessed Sept 25, 2016).
21. 21 Burotto, M, Wilkerson, J, Stein, W, et al. Continuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as example. PLoS One, 9, 2014, e96316.
22. 22 Berthold, DR, Pond, GR, Soban, F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the Tax 327 study. J Clin Oncol 26 (2008), 242–245.
23. 23 Sosman, JA, Kim, KB, Schuchter, L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366 (2012), 707–714.
24. 24 Hauschild, A, Grob, JJ, Demidov, LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380 (2012), 358–365.
25. 25 Cortes, J, O'Brien, S, Kantarjian, H, Discontinuation of imatinib therapy after achieving a molecular response. Blood 104 (2004), 2204–2205.
26. 26 Ananthnarayan, S, Bahng, J, Roring, J, et al. Time course of imaging changes of GBM during extended bevacizumab treatment. J Neurooncol 88 (2008), 339–347.
27. 27 André, F, Zielinski, CC, Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann Oncol 23:suppl 6 (2012), vi46–vi51.
28. 28 Eymard, JC, Oudard, S, Gravis, G, et al. Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study. BJU Int 106 (2010), 974–978.
29. 29 Scher, HI, Morris, MJ, Stadler, WM, et al. The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC). Proc Am Soc Clin Oncol, 33(suppl), 2015 abstr 5000.
30. 30 Landgren, O, Mailankody, S, Update on second primary malignancies in multiple myeloma: a focused review. Leukemia 28 (2014), 1423–1426.
31. 31 Gentzler, RD, Johnson, ML, Complex decisions for first-line and maintenance treatment of advanced wild-type non-small cell lung cancer. Oncologist 20 (2015), 299–306.
32. 32 Gerber, DE, Schiller, JH, Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea. J Clin Oncol 31 (2013), 1009–1020.
33. 33 Lange, A, Prenzler, A, Frank, M, et al. A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC). BMC Pulm Med, 14, 2014, 192.
34. 34 Sweeney, C, Chen, Y-H, Carducci, MA, et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): an ECOG-led phase III randomized trial. Proc Am Soc Clin Oncol, 32(5 suppl), 2014 abstr LBA2.
35. 35 Antonarakis, ES, Eisenberger, MA, Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from experiences. J Clin Oncol 31 (2013), 1709–1712.